Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
US6338963B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 19, 1999 |
| Grant date | Jan 15, 2002 |
| Priority date | — |
| Expiry date | Oct 19, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.